Results 11 to 20 of about 7,686 (201)
Nefrología, 2022 Resumen: Antecedentes y objetivo: Describir las características clínicas de los pacientes tratados con evolocumab, las razones del inicio de la terapia y los efectos del tratamiento en la fase inicial de disponibilidad de evolocumab en las unidades de ...
Marian Goicoechea +15 more
doaj +1 more source
Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9): The Multifaceted Biology, Diseases, and Pharmaceutical Interventions. [PDF]
MedComm (2020)Summary of PCSK9 inhibitor mechanisms. PCSK9 inhibitors (PCSK9‐i) primarily lower LDL‐cholesterol (LDL‐C) by blocking PCSK9‐mediated degradation of hepatic LDL receptors (LDLR), enhancing LDL clearance. Beyond LDLR‐dependent effects, PCSK9‐i exert multiple benefits via LDLR‐independent pathways.
Kuang J, Hao L, Zhang M, Yang Z.
europepmc +2 more sources
Glycaemic effects of non-statin lipid-lowering therapies [PDF]
, 2016 Since the publication of the JUPITER trial, attention has been focused on the adverse glycemic effects of statin therapy. Although the modest increase in the risk of new diabetes mellitus is outweighed by the reduction in cardiovascular events for ...
Collins, Patrick D., Sattar, Naveed
core +3 more sources
Frontiers in Cardiovascular Medicine, 2022 AimsThe efficacy of anti-proprotein convertase subtilisin/Kexin type 9 (PCSK9) monoclonal antibodies in patients with atherosclerotic cardiovascular disease (ASCVD) remains unclear.
Hong-Fei Wang +17 more
doaj +1 more source
Effect of evolocumab on cholesterol synthesis and absorption[S]
Journal of Lipid Research, 2016 The effects of cholesterol-lowering drugs, including those that reduce cholesterol synthesis (statins) and those that reduce cholesterol absorption (ezetimibe), on cholesterol absorption and synthesis are well understood. Proprotein convertase subtilisin/
Matthew Peach +7 more
doaj +1 more source
Journal of Cardiovascular Development and Disease, 2022 Elevated circulating lipoprotein(a) levels are associated with an increased risk of cardiovascular events. We reported that early initiation of evolocumab, a proprotein convertase subtilisin/kexin type 9 inhibitor, in addition to a statin substantially ...
Tomoaki Okada +9 more
doaj +1 more source
Unpacking and understanding the impact of proprotein convertase subtilisin/kexin type 9 inhibitors on apolipoprotein B metabolism [PDF]
, 2017 No abstract ...
Packard, Chris J.
core +1 more source
Efficacy of single-dose evolocumab injection in early-phase acute myocardial infarction: a retrospective single-center study [PDF]
The Korean Journal of Internal MedicineBackground/Aims Achieving rapid reduction of low-density lipoprotein cholesterol (LDL-C) levels below 55 mg/dL in patients with acute myocardial infarction (AMI) can be challenging with statins alone.
Yongcheol Kim +6 more
doaj +1 more source
Systematic review and network meta-analysis on the efficacy of evolocumab and other therapies for the management of lipid levels in hyperlipidemia [PDF]
, 2017 Background: The proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors evolocumab and alirocumab substantially reduce low‐density lipoprotein cholesterol (LDL‐C) when added to statin therapy in patients who need additional LDL‐C reduction ...
Bray, Sarah +13 more
core +1 more source